Turkey has updated the pricing regime for human medicinal products. Changes apply particularly to price calculation methods and caps, including where changes occur to price preserved reference products and the original reference price. The changes also allow price increases caused by currency fluctuations (relative to the Euro) to enter into effect quicker.
The Decision Regarding Pricing of Human Medicinal Product (“Decision”) was approved by Council of Ministers’ Decision number 2017/9901 on 6 February 2017.
Notable changes introduced by the Decision include:
- The ceiling price will now be 80% of the real reference price for price preserved reference products which were presented to the market in any pharmaceutical method, anywhere in the world, before 1 August 1987.
- If the original reference price drops below 60% of a reference product’s value:
- Increases between 60% and 100% of the base value: The reference price may not be more than 60% of the original reference price.
- Increases of more than 100% of the base value: The reference price will be calculated as 60% of the new original reference price.
- If the original reference price drops below 80% of a price preserved reference product’s value:
- Increases between 80% and 100% of the base value: The reference price may not be more than 80% of the original reference price.
- Increases of more than 100% of the base value: The reference price will be calculated as 80% of the new original reference price.
- A provision is repealed regarding price changes for selling products to approved Turkish stores from a reference price or reference country.
- Changes to product prices caused by increases in the Euro’s value will now enter into effect five days after the Commission Decision is announced, instead of 45 days. Changes due to decreases in the Euro’s value will continue to take effect 45 days after announcement.
Please see this link for full text of the Decision (only available in Turkish).
